A Phase II Trial of Weekly High-Dose Folinic Acid and 5-Fluorouracil in Combination with Epirubicin as Salvage Chemotherapy in Advanced Breast Cancer
作者:
H. Stöger,
M. Schmid,
T. Bauernhofer,
R.M. Moser,
F. Ploner,
E. Derstvenscheg,
A.K. Kasparek,
I. Kuss,
M. Wilders-Truschnig,
C. Lackner,
P. Steindorfer,
H. Samonigg,
期刊:
Oncology
(Karger Available online 1994)
卷期:
Volume 51,
issue 6
页码: 518-522
ISSN:0030-2414
年代: 1994
DOI:10.1159/000227397
出版商: S. Karger AG
关键词: Folinic acid;Fluorouracil;Epirubicin;Weekly schedule;Second-line therapy;Advanced breast cancer
数据来源: Karger
摘要:
Twenty-five patients with advanced breast cancer (ABC) who had failed from first-line chemotherapy entered into a phase II study employing weekly 5-fluorouracil (FU) 350 mg/m2, folinic acid (FA) 500 mg/m2, and epirubicin (EPI) 35 mg/m2, for a maximum of 18 cycles. Twenty-three patients were evaluable for response. One achieved a complete response and 7 showed a partial response, for an objective response rate of 35%; 7 (31%) patients achieved a stabilization of the disease, while 8 (35%) patients progressed under treatment. The median duration of response was 6 months and median survival amounted to 10.6 months. Side effects were in general mild with grade III leukopenia in 5 patients and grade IV leukopenia in 1 patient. Other toxicity included nausea and vomiting (88%), diarrhea (26%), stomatitis (40%) and alopecia (84%), but all of them mainly restricted to WHO grade I and II. Our results suggest that the combination of high-dose FA, FU, and EPI can be safely administered in the investigated schedule and represents an attractive alternative in the search for second-line therapies that combine effectiveness with acceptable toxicity in the treatment of refractory ABC.
点击下载:
PDF
(2406KB)
返 回